Bill Welch | Chief Executive Officer
Bill Welch joined Trovagene as Chief Executive Officer and member of the Board of Directors in 2016.
Prior to Trovagene, Mr. Welch was President and CEO at Sequenom Inc. where he introduced the first non-invasive prenatal test (NIPT) utilizing a maternal blood sample to identify fetal chromosomal abnormalities and helped establish a $3.0B global NIPT market. Prior to Sequenom, Mr. Welch was Senior Vice President, Chief Commercial Officer at Monogram Biosciences, a leader in HIV and oncology diagnostic testing services. Previously, Mr. Welch was Vice President of Sales and Marketing at La Jolla Pharmaceutical, an immunology based Biotechnology Company, developing and commercializing innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Mr. Welch also worked at Dade Behring MicroScan as Vice President of Global Marketing. Mr. Welch entered the healthcare industry with Abbott Laboratories where he held progressive management positions in therapeutics and medical devices.
Mr. Welch interests include the consumerization of healthcare, particularly in precision medicine and genomics. He has led numerous commercial and development programs through the FDA regulatory process for drugs and devices, from NDA’s to in-vitro diagnostics Class II 510(k) & Class III PMA as well as CLIA and CAP laboratory certifications.
Mr. Welch has an MBA from Harvard University and a BS in Chemical Engineering from University of California at Berkeley.